Terry Smith Fundsmith LLP
Terry Smith is the founder and CEO of Fundsmith, a firm known for a concentrated portfolio of high-quality global companies. His approach favors simple, understandable businesses with high returns on capital and the ability to reinvest at attractive rates. Smith’s annual letters and plain-spoken commentary have made Fundsmith a frequent reference point for long-only quality investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medpace
MEDP
|
+$43.3M |
| 2 |
Doximity
DOCS
|
+$34.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$363M |
| 2 |
Microsoft
MSFT
|
+$304M |
| 3 |
Visa
V
|
+$278M |
| 4 |
Meta Platforms (Facebook)
META
|
+$182M |
| 5 |
Automatic Data Processing
ADP
|
+$165M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.66% |
| 2 | Healthcare | 22.21% |
| 3 | Consumer Staples | 18.08% |
| 4 | Communication Services | 16.91% |
| 5 | Consumer Discretionary | 8.04% |
Similar funds
Terry Smith's Q4 2024 Portfolio in Review
As of Q4 2024, Terry Smith held 42 positions worth $23.5B, down 7.2% from $25.3B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Terry Smith withdrew a net $1.78B in Q4 2024, closing 4 positions and reducing 21 holdings. Its most notable exit was Apple, an estimated $363M position sold in full.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Staples.
Against the trend, Terry Smith opened a new position in Medpace worth $42.4M.
- Terry Smith's largest Q4 2024 buy was Medpace: 127,537 shares worth $42.4M.
- Terry Smith's biggest Q4 2024 reduction was Microsoft, cutting an estimated $304M.
- Terry Smith fully exited Apple in Q4 2024, selling an estimated $363M.
- Terry Smith's ten largest holdings make up 70% of its $23.5B portfolio in Q4 2024.
- Terry Smith opened 2 new positions and closed 4 in Q4 2024.
- Terry Smith's portfolio value fell 7.2% quarter-over-quarter to $23.5B.
Based on Fundsmith LLP's 13F filing for Q4 2024, filed 14 Feb 2025.